Innate Pharma SA
Business
Innate Pharma S.A. is a clinical-stage biotechnology company developing immunotherapies for cancer patients using antibody-engineering expertise and innovative target identification. The company is advancing a portfolio of differentiated antibody therapeutics, including lacutamab (anti-KIR3DL2), IPH4502 (Nectin-4-targeting ADC), and monalizumab (anti-NKG2A), along with proprietary ANKET® platform for NK cell engagers. Innate has established collaborations with AstraZeneca and Sanofi to accelerate development and commercialization while funding its proprietary pipeline through upfront and milestone payments.
Summary from 20-F filed 2026-04-01
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-49.18M |
| Total assets | $62.72M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Innate Pharma SA's CIK number?
Innate Pharma SA's SEC CIK number is 0001598599 (1598599). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Innate Pharma SA's SEC filings?
All of Innate Pharma SA's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.